文献速递湿疹皮炎与荨麻疹

Tapinarof乳膏治疗青少年及成人特应性皮炎的2b期随机临床试验疗效与患者报告结局

Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
PubMed 文献 · J Am Acad Dermatol · 2020-06-02

这项2b期双盲、赋形剂对照试验将青少年和成人特应性皮炎患者随机分配至Tapinarof乳膏0.5%、1%或赋形剂组,每日一次或两次,治疗12周并随访4周。结果显示,Tapinarof组在第12周IGA应答率、EASI较基线改善≥75%/90%的比例、EASI评分及受累体表面积方面均优于赋形剂组,患者报告的AD和瘙痒症状严重程度改善更明显,POEM在各组均有改善,大多数不良事件为轻中度。

要点

  • Tapinarof 1%每日两次组第12周IGA应答率显著高于赋形剂组。
  • 除0.5%每日一次和0.5%每日两次组外,Tapinarof组EASI较基线改善≥75%/90%的比例显著更高。
  • 所有Tapinarof组EASI评分显著改善,除0.5%每日两次组外受累体表面积显著减少。

核心结论

  • Tapinarof乳膏是特应性皮炎外用药物治疗开发中潜在的 important advance。

研究设计与样本

  • 2b期、双盲、赋形剂对照研究,将青少年和成人特应性皮炎患者随机分配至Tapinarof乳膏0.5%、1%或赋形剂组,每日一次或两次,治疗12周并随访4周。
  • 共随机分配247例患者,其中191例完成研究。

主要发现

  • 第12周IGA应答率在Tapinarof组高于赋形剂组,其中Tapinarof 1%每日两次组达到统计学显著性。
  • 除0.5%每日一次和0.5%每日两次组外,Tapinarof组EASI较基线改善≥75%/90%的比例显著高于赋形剂组。
  • 所有Tapinarof组EASI评分显著改善;除0.5%每日两次组外,Tapinarof组受累体表面积显著减少。
  • 更多Tapinarof组患者报告AD和瘙痒症状严重程度为非常/中度改善,所有组均观察到POEM改善。
  • 大多数不良事件为轻度或中度。

临床怎么用

  • 对于青少年和成人特应性皮炎,Tapinarof乳膏1%每日两次可能改善 Investigator Global Assessment 应答和EASI应答。

局限性

  • 需要更大规模的前瞻性研究来验证所报告的分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent under investigation for atopic dermatitis (AD) and psoriasis treatment. METHODS: A phase 2b, double-blind, vehicle-controlled study randomly assigned adolescents and adults with AD to receive tapinarof cream 0.5%, 1%, or vehicle, once or twice daily, for 12 weeks with a 4-week follow-up. Outcomes included Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), body surface area affected, pruritus numeric rating scale scores, patients' impressions of AD and pruritus symptom severity, and Patient-Oriented Eczema Measure (POEM) scores. RESULTS: Overall, 191 of 247 randomized patients completed the study. Week 12 IGA responses were higher in the tapinarof groups versus the vehicle group, reaching statistical significance with tapinarof 1% twice daily, ≥75%/90% improvement in EASI from baseline were significantly higher in the tapinarof groups (except 0.5% once daily and 0.5% twice daily), EASI scores were significantly improved in all tapinarof groups, and body surface area affected was significantly reduced in the tapinarof groups (except 0.5% twice daily). More patients reported AD and pruritus symptom severity as very/moderately improved in tapinarof groups, and POEM improvements were observed in all groups. Most adverse events were mild or moderate. LIMITATIONS: Larger prospective studies are required to confirm the reported analyses. CONCLUSIONS: Tapinarof is a potential important advance in topical medicine development for AD.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Stein Gold L, Soung J, et al. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol. 2020. PMID: 32502588. doi:10.1016/j.jaad.2020.05.135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。